Author: Kim, Eun; Erdos, Geza; Huang, Shaohua; Kenniston, Thomas; Falo, Louis D.; Gambotto, Andrea
Title: Preventative Vaccines for Zika Virus Outbreak: Preliminary Evaluation Document date: 2016_10_3
ID: jzcyxjxt_25
Snippet: In this study, we describe the construction and immunological evaluation of two ZIKV vaccine candidates. Our initial evaluations indicated that the ZIKV vaccines Ad5.ZIKV-Efl and MNA-ZIKV-rEfl elicited a humoral immune response in immunized C57BL/6 mice. The humoral a c *** *** b *** n.s. *** * *** Fig. 2 . Characterization of ZIKV-specific immune responses induced by Ad5.ZIKV-Efl and MNA-ZIKV-rEfl. (a) Experimental schedule representing the immu.....
Document: In this study, we describe the construction and immunological evaluation of two ZIKV vaccine candidates. Our initial evaluations indicated that the ZIKV vaccines Ad5.ZIKV-Efl and MNA-ZIKV-rEfl elicited a humoral immune response in immunized C57BL/6 mice. The humoral a c *** *** b *** n.s. *** * *** Fig. 2 . Characterization of ZIKV-specific immune responses induced by Ad5.ZIKV-Efl and MNA-ZIKV-rEfl. (a) Experimental schedule representing the immunization timeline. C57BL/6 mice (n = 5/group) were immunized subcutaneously with 1 × 10 11 viral particles of Ad.ZIKV-Efl or PBS as a negative control and boosted intranasally with the same amount of adenovirus two weeks later. MNA-ZIKV-rEfl was administered through intradermal delivery. (b) ZIKV-specific IgG antibody levels were measured at the indicated time points using ELISA. (c) The ZIKVneutralizing titers at week 6 post-immunization were measured using Vero cells by determining the reciprocal of the highest serum dilution still giving a 50% reduction in plaque number by 50% (PRNT 50 ), relative to samples incubated with pre-immunized control pooled sera. Statically significant differences (Tukey's test) are marked by bars and asterisks. *, P b 0.05; ***, P b 0.001. The same mean of neutralization was detected in two independent neutralizing tests with combined mouse sera. response was characterized by high titers of antibodies to E antigen as confirmed by ELISA, as well as neutralizing titers confirmed by PRNT 50 assay. Importantly, in pups born to immunized dams, ZIKV-specific immunity was passively transferred and protected them from day 7 challenge of 10 5 pfu of the ZIKV DAKAR41542 strain. The Ad5.ZIKV-Efl and MNA-ZIKV-rEfl vaccines were engineered using the 2015 Brazil ZIKV strain BeH815744. The BeH815744 strain E protein differs from the DAKAR41542 strain E protein used for challenge in three amino acids (98% identity). In general, the ZIKV envelope protein is highly conserved.
Search related documents:
Co phrase search for related documents- amino acid and antibody level: 1, 2, 3, 4, 5, 6
- amino acid and envelope protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- amino acid and high titer: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- antibody high titer and envelope protein: 1
- antibody high titer and high titer: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- antibody high titer and IgG antibody level: 1
- antibody level and ELISA confirm: 1
- antibody level and envelope protein: 1, 2, 3
- antibody level and high titer: 1, 2, 3, 4, 5, 6
- antibody level and IgG antibody level: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- envelope protein and high titer: 1, 2, 3, 4
- envelope protein and IgG antibody level: 1
- high titer and IgG antibody level: 1
Co phrase search for related documents, hyperlinks ordered by date